262 related articles for article (PubMed ID: 34597729)
21. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
22. INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.
Panés J; Bouma G; Ferrante M; Kucharzik T; Nachury M; de la Portilla de Juan F; Reinisch W; Selvaggi F; Tschmelitsch J; Brett NR; Ladouceur M; Binek M; Hantsbarger G; Campbell-Hill S; Karki C; Buskens C
Inflamm Bowel Dis; 2022 Nov; 28(11):1737-1745. PubMed ID: 35099555
[TBL] [Abstract][Full Text] [Related]
23. A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's Disease.
Lightner AL; Otero-Pineiro A; Reese J; Ream J; Nachand D; Adams AC; VanDenBossche A; Kurowski JA
Inflamm Bowel Dis; 2023 Dec; 29(12):1912-1919. PubMed ID: 37263018
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.
Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Inflamm Bowel Dis; 2022 Feb; 28(2):218-225. PubMed ID: 33847351
[TBL] [Abstract][Full Text] [Related]
25. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
J Gastroenterol; 2020 Mar; 55(3):291-306. PubMed ID: 31836930
[TBL] [Abstract][Full Text] [Related]
26. Long-term Efficacy of Vedolizumab for Crohn's Disease.
Vermeire S; Loftus EV; Colombel JF; Feagan BG; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
J Crohns Colitis; 2017 Apr; 11(4):412-424. PubMed ID: 27683798
[TBL] [Abstract][Full Text] [Related]
27. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.
Dulai PS; Singh S; Jiang X; Peerani F; Narula N; Chaudrey K; Whitehead D; Hudesman D; Lukin D; Swaminath A; Shmidt E; Wang S; Boland BS; Chang JT; Kane S; Siegel CA; Loftus EV; Sandborn WJ; Sands BE; Colombel JF
Am J Gastroenterol; 2016 Aug; 111(8):1147-55. PubMed ID: 27296941
[TBL] [Abstract][Full Text] [Related]
28. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
29. Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.
Barreiro-de Acosta M; Fernández-Clotet A; Mesonero F; García-Alonso FJ; Casanova MJ; Fernández-de la Varga M; Cañete F; de Castro L; Gutiérrez A; Sicilia B; Cano V; Merino O; de Francisco R; González-Partida I; Surís G; Torrealba L; Ferreiro-Iglesias R; Castro B; Márquez L; Sobrino A; Elorza A; Calvet X; Varela P; Vicente R; Bujanda L; Lario L; Manceñido N; García-Sepulcre MF; Iglesias E; Rodríguez C; Piqueras M; Ferrer Rosique JÁ; Lucendo AJ; Benítez O; García M; Olivares D; González-Muñoza C; López-Cauce B; Morales Alvarado VJ; Spicakova K; Brotons A; Bermejo F; Almela P; Ispízua N; Gilabert P; Tardillo C; Muñoz F; Navarro P; Madrigal Domínguez RE; Sendra P; Hinojosa E; Sáinz E; Martín-Arranz MD; Carpio D; Ricart E; Caballol B; Núñez L; Barrio J; Gisbert JP; Iborra M; Calafat M; Hernández V; Muñoz Pérez R; Cabriada JL; Domènech E; Rodríguez-Lago I;
Am J Gastroenterol; 2023 Jun; 118(6):1036-1046. PubMed ID: 36516073
[TBL] [Abstract][Full Text] [Related]
31. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
32. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease.
Rasul I; Wilson SR; MacRae H; Irwin S; Greenberg GR
Am J Gastroenterol; 2004 Jan; 99(1):82-8. PubMed ID: 14687146
[TBL] [Abstract][Full Text] [Related]
33. Vedolizumab in Crohn's disease with rectal fistulas and presacral abscess: A case report.
Yeh H; Kuo CJ; Wu RC; Chen CM; Tsai WS; Su MY; Chiu CT; Le PH
World J Gastroenterol; 2021 Feb; 27(5):442-448. PubMed ID: 33584075
[TBL] [Abstract][Full Text] [Related]
34. A Preclinical Validation of Iron Oxide Nanoparticles for Treatment of Perianal Fistulizing Crohn's Disease.
Cazelles A; Collard MK; Lalatonne Y; Doblas S; Zappa M; Labiad C; Cazals-Hatem D; Maggiori L; Treton X; Panis Y; Jarry U; Desvallées T; Eliat PA; Pineau R; Motte L; Letourneur D; Simon-Yarza T; Ogier-Denis E
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955465
[TBL] [Abstract][Full Text] [Related]
35. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
36. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.
Panés J; García-Olmo D; Van Assche G; Colombel JF; Reinisch W; Baumgart DC; Dignass A; Nachury M; Ferrante M; Kazemi-Shirazi L; Grimaud JC; de la Portilla F; Goldin E; Richard MP; Diez MC; Tagarro I; Leselbaum A; Danese S;
Gastroenterology; 2018 Apr; 154(5):1334-1342.e4. PubMed ID: 29277560
[TBL] [Abstract][Full Text] [Related]
37. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.
Sands BE; Van Assche G; Tudor D; Akhundova-Unadkat G; Curtis RI; Tan T
Inflamm Bowel Dis; 2019 Jul; 25(8):1375-1382. PubMed ID: 30615117
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
39. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
[TBL] [Abstract][Full Text] [Related]
40. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
Papamichael K; Cheifetz AS
World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
